Today's Morning Top Gainers (MPS, BK, UAUA, LXK, NVAX)

MPS Group, Inc. (NYSE: MPS) is today’s top percentage gainer in morning trade and surged 21.72% today to $13.56 on an unusual huge volume of 10.13 million shares after Adecco , the world's largest staffing company, is buying American rival MPS Group for $1.3 billion, boosting its high-margin and more recession-resilient professional staffing business.

The Bank of New York Mellon Corporation (NYSE: BK) climbed 4.70% to $28.51 on huge volume of 5.77 million shares after the company reported a third-quarter loss of $2.458 billion, or $2.05 per share. Excluding special items, BK earned a profit of 54 cents per share, beating analysts' estimates of 47 cents per share.

UAL Corporation (NASDAQ: UAUA) is also moving sharply by 8.26% to $7.88 on over 6.12 million shares after it reported third-quarter loss of$57 million, or 39 cents a share, compared to a loss of $792 million, or $6.62 a share, in the same period a year ago. Excluding items, UAL lost 43 cents a share. Revenue fell 20% to $4.4 billion from $5.6 billion. Analysts polled by FactSet Research estimated, on average, a loss per share of 98 cents and sales of $4.3 billion.

Lexmark International, Inc. (NYSE: LXK) soared 11.21% now trades at $25.10 on high volume of 3.10 million shares after posted third-quarter net income of $10 million, or 13 cents a share, against $36.6 million, or 42 cents a share, in the year-ago period. Adjusted earnings were 65 cents versus 63 cents. Strong demand drove growth, said Paul J. Curlander, chairman and chief executive. A survey of analysts by FactSet Research produced a consensus estimate for the quarter of 46 cents a share.

Novavax, Inc. (NASDAQ: NVAX) today moved up 5% to $3.94 with over 2.30 million shares changed hand after he Rockville, Md., biotech company, said on Tuesday that it began a two-stage clinical study in Mexico of a vaccine for H1N1 influenza. The company is collaborating with GE Healthcare and Avimex Laboratories, the Mexico City producer of biological and pharmaceutical products. Avimex is helping finance the trial, and if the drug is cleared for marketing, the Mexican company is expected to distribute the vaccine in Mexico in 2010, Novavax said. GE Healthcare is providing its single-use bioprocessing technologies for vaccine production.